期刊文献+

Ⅲ型β-微管蛋白和多药耐药基因1蛋白表达与非小细胞肺癌生物学特性的相关性 被引量:2

Correlation of the expression of III β-tubulin and MDR1 protein with biological features of non-small cell lung cancer
原文传递
导出
摘要 目的 探讨Ⅲ型β-微管蛋白(Ⅲβ-tubulin)和多药耐药基因1(MDR1)蛋白在非小细胞肺癌(NSCLC)中的表达特征及临床意义.方法 应用免疫组化法检测158例NSCLC组织中Ⅲβ-tubulin和MDR1蛋白的表达,应用Western blot检测新鲜NSCLC组织及相应癌旁正常组织中Ⅲβ-tubulin和MDR1蛋白的表达,并分析其表达与NSCLC生物学特性的关系.结果 Ⅲβ-tubulin和MDR1蛋白在NSCLC中的阳性表达率分别为65.2%和51.3%.Western blot结果显示,Ⅲβ-tubulin和MDR1蛋白在NSCLC组织中的表达明显高于癌旁正常肺组织(P<0.01).Ⅲβ-tubulin在中、高分化腺癌中的表达明显低于低分化腺癌(P<0.01),肺腺癌中MDR1蛋白的表达明显高于鳞癌和大细胞未分化癌(P<0.01).Ⅲβ-tubulin在Ⅲ~Ⅳ期NSCLC中的表达高于Ⅰ~Ⅱ期(P<0.05),而MDR1蛋白的表达差异无统计学意义(P>0.05).Ⅲβ-tubulin和MDR1蛋白阳性表达与患者年龄、性别、肿瘤大小及淋巴结状态无明显相关性(P>0.05).结论 Ⅲβ-tubulin和MDR1蛋白在NSCLC的发生、发展中有一定作用,可作为判断NSCLC预后的重要指标. Objective To explore the expression of Ⅲ β-tubulin and MDR1 protein in patients with non-small cell lung cancer (NSCLC), and to clarify its clinical significance. Methods Paraffin embedded tissues from 158 primary non-small cell lung cancers and para-cancerous lung tissues were investigated for the expression of Ⅲ β-tubulin and MDR1 protein by immunohistochemistry, as well as in freshly-taken NSCLC tissues by Western blot. The relationship between the expression of Ⅲ β-tubulin and MDR1 and the biological features of lung cancer was analyzed. Results The positive rate of Ⅲ β-tubulin and MDR1 protein expression in lung cancer tissues was 65.19% and 51.27%, respectively. Western blot analysis showed that the level of of Ⅲ β-tubulin and MDR1 protein in NSCLC tissues was remarkably higher than that in normal tissues ( P 〈0.01). The expression of Ⅲ β-tubulin in stage Ⅲ-Ⅳ cases was significantly higher than that in stage Ⅰ - Ⅱ cases ( P 〈 0.05 ), while the expression of MDR1 protein showed no significant difference (P 〉 0.05). The positive rate of Ⅲ β-tubulin expression in well-moderate pathological grades was lower than that in poor ones. The positive rate of MDR1 expression in adenocarcinoma was higher than that in squamous cell carcinoma and large cell undifferentiated cancers ( P 〈 0. 01 ). The positive rate of expression of MDR1 protein and Ⅲ β-tubulin was not correlated with sex, age, tumor size and lymph node metastasis (P 〉 0.05 ). Conclusion The expression of Ⅲ β-tubulin and MDR1 may play an important role in the development and progression of human non-small cell lung cancer, and could be looked as an important index for judging the prognosis of lung cancer.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2010年第10期762-766,共5页 Chinese Journal of Oncology
关键词 非小细胞肺 Ⅲ型β-微管蛋白 MDR1蛋白 免疫组织化学 Carcinoma, non-small-cell lung Ⅲ β-tubulin MDR1 protein Immunohistochemistry
  • 相关文献

参考文献18

  • 1Rao J.Targeting actin remodeling profiles for the detection and management of urothelial cancers:a perspective for bladder cancer research.Front Biosci,2002,7:e1-8.
  • 2Herblot S,Chastagner P,Samady L,et al.IL-2-dependent expression of genes involved in cytoskeleton organization,oncogene regulation,and transcriptional control.J Immunol,1999,162:3280-3288.
  • 3Dumontet C,Jordan MA,Lee FF.Ixabepilone:targeting beta Ⅲ -tubulin expression in taxane-resistant malignancies.Mol Cancer Ther,2009,8:17-25.
  • 4Gan PP,Kavallaris M.Tubulin-targeted drug action:functional significance of class Ⅱ and class Ⅳb beta-tubulin in vinca alkaloid sensitivity.Cancer Res,2008,68:9817-9824.
  • 5Azuma K,Sasada T,Kawahara A,et al.Expression of ERCC1 and class Ⅲ beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.Cancer Chemother Pharmacol,2009,64:565-573.
  • 6Ohishi Y,Oda Y,Basaki Y,et al.Expression ofbeta-tubulin isotypes in human primary ovarian carcinoma.Gynecol Oncol,2007,105:586-592.
  • 7Sè ve P,Mackey J,Isaac S,et al.Class Ⅲ beta-tubulin expression in tumor cells predicts response and outcome in patients with nonsmall cell lung cancer receiving paclitaxel.Mol Cancer Ther,2005,4:2001-2007.
  • 8Katsetos CD,Kontogeorgos G,Geddes JF,et al.Differential distribution of the neuron-associated class Ⅲ beta-tubulin in neuroendocrine lung tumors.Arch Pathol Lab Med,2000,124:535-544.
  • 9Sève P,Lai R,Ding K,et al.Class Ⅲ beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer:analysis of NCIC JBR.10.Clin Cancer Res,2007,13:994-999.
  • 10Sève P,Dumontet C.Is class Ⅲ β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol,2008,9:168-175.

同被引文献18

  • 1Li W,Deng J,Tang JX.Combined effects methylation of FHIT,RASSF1A and RARβgenes on non-small cell lung cancer in the Chinese population[J].Asian Pac J Cancer Prev,2014,15(13):5233-5237.
  • 2De Stefani E,Boffetta P,Ronco AL,et al.Squamous and small cell carcinomas of the lung:similarities and differences concerning the role of tobacco smoking[J].Lung Cancer,2005,47(1):1-8.
  • 3Palmisano WA,Divine KK,Saccomanno G,et al.Predicting lung cancer by detecting aberrant promoter methylation in sputum[J].Cancer Res,2000,60(21):5954-5958.
  • 4Chaudhuri AR,Khan IA,Prasad V,et al.The tumor suppressor protein Fhit.A novel interaction with tubulin[J].J Biol Chem,1999,274(34):24378-24382.
  • 5Wu DW,Lee MC,Hsu NY,et al.FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction[J].Oncogene,2015,34(19):2505-2515.
  • 6《诊断性可弯曲支气管镜应用指南(2008年版)》[J].中华结核和呼吸杂志,2008,31(1):14-17. 被引量:306
  • 7Yoshizawa A, Motoi N, Riely G J, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases [ J ]. Mod Pathol, 2011,24 ( 5 ) : 653 - 64.
  • 8Travis W D, Brambilla E, Riely G J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials [J]. J Clin Oncol, 2013,31(8) :992-1001.
  • 9Takahashi M, Shigematsu Y, Ohta M, et al. Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocareinoma and can be predicted by radiologic parameters[J].J Thorac Csrdiovasc Surg, 2014,147 ( 1 ) :54 - 9.
  • 10Yuan S F, Zhu L J, Zheng W E, et al. Expression of β-tubulin Ⅲ and Survivin in advance stage breast cancer correlates with che-motheraputic effects of doeetaxel [J]. Asian Pac J Cancer Prey, 2012,13(1) :361 -5.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部